On April 19, 2022, ADAPTIS received FDA approval for ANDA213796, granting the company rights to manufacture a generic version of an undisclosed substance. The green light is expected to bolster ADAPTIS’s product portfolio by enabling the rapid capture of market share in the corresponding therapeutic segment.